{'fraction_non_alphanumeric': 0.020444444444444446, 'fraction_numerical': 0.010666666666666666, 'mean_word_length': 5.74251497005988, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Comparison between effects of morning and evening administration of effervescent calcium carbasalate (equivalent of 160 mg aspirin) on the gastroduodenal mucosa in healthy volunteers].

The aim of this randomised, cross-over trial was to compare the gastroduodenal tolerability and anti-aggregating effect of effervescent calcium carbasalate (ECC equivalent to 160 mg aspirin) given once daily either in the morning or in the evening. Twelve healthy volunteers received calcium carbasalate for 2 periods of 5 days (21 days of wash-out between the 2 periods). The principal criterion was the gastroduodenal tolerability assessed by the total number of lesions at upper gastro-intestinal endoscopy. The same treatment-blinded endoscopist performed all evaluations. Efficacy was evaluated by thromboxane B2 measurement and collagen-induced platelet aggregation tests. No difference was observed between morning and evening administration of ECC on gastroduodenal tolerability and platelet agregation. ECC was very well tolerated as assessed by upper gastrointestinal endoscopy and almost totally inhibited platelet aggregation.